United Therapeutics is a publicly-traded biotech/pharmaceutical public benefit corporation that develops novel pharmaceutical therapies for rare diseases and technologies that expand the availability of transplantable organs. The company has six FDA-approved therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and neuroblastoma, and is working to create manufactured organs to address the transplant organ shortage.
